These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
8. Prasugrel: Clinical development and therapeutic application. Guerra DR; Tcheng JE Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231 [TBL] [Abstract][Full Text] [Related]
9. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Packard KA; Campbell JA; Knezevich JT; Davis EM Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457 [TBL] [Abstract][Full Text] [Related]
10. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610 [TBL] [Abstract][Full Text] [Related]
11. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184 [TBL] [Abstract][Full Text] [Related]
12. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C; Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364 [TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Steiner S; Moertl D; Chen L; Coyle D; Wells GA Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948 [TBL] [Abstract][Full Text] [Related]
14. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions. White HD Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598 [TBL] [Abstract][Full Text] [Related]
15. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR; Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596 [TBL] [Abstract][Full Text] [Related]
16. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242 [TBL] [Abstract][Full Text] [Related]
17. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
18. Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Norgard NB; Dinicolantonio JJ Postgrad Med; 2013 Jul; 125(4):91-102. PubMed ID: 23933898 [TBL] [Abstract][Full Text] [Related]
19. Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes. Aronow WS Postgrad Med; 2013 Jan; 125(1):51-8. PubMed ID: 23391671 [TBL] [Abstract][Full Text] [Related]
20. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice. Golino P J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]